| Name | CMPF |
| Description | CMPF is a microtubule protein inhibitor that can be used to study tumors. |
| In vitro | CMPF is tightly bound to albumin but only moderately inhibits T4 binding in a direct manner (10-14% at 0.3 mM). However, CMPF effectively displaces competitive T4 binding molecules from albumin, such as acidic drugs and free fatty acids. Therefore, CMPF may indirectly influence T4 binding to albumin by increasing the serum concentration of competitive binding molecules, particularly free fatty acids such as oleic acid.[6] |
| In vivo | CMPF is highly albumin-bound and accumulates in the serum of uremic patients to concentrations in excess of 0.2 mM. Its primary effect is to inhibit cellular transport and subsequent deiodination of thyroxine (T4).[5] [6] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMF : 27 mg/mL (112.38 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (8.32 mM), Sonication is recommended.
DMSO : 27 mg/mL (112.38 mM), Sonication is recommended.
Ethanol : 27 mg/mL (112.38 mM), Sonication is recommended.
|
| Keywords | Tubulin | MicrotubuleAssociated | Microtubule Associated |
| Inhibitors Related | Sucrose | Aceglutamide | L-Pyroglutamic acid | Nicotinamide riboside malate | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Formamide | Glycerol | Thymidine | Corn starch | Hyaluronic acid sodium (MW 20 kDa) | Gluconate Calcium |
| Related Compound Libraries | Bioactive Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Human Metabolite Library | High-Efficiency Gene Editing Small Molecule Library |
United States
